Design, synthesis, and anti-mycobacterial evaluation of 1,8-naphthyridine-3-carbonitrile analogues-Reference-Cited by-同舟云学术

Design, synthesis, and anti-mycobacterial evaluation of 1,8-naphthyridine-3-carbonitrile analogues

Published:2024 Issue:31 Volume:14 Page:22676-22689
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Khetmalis Yogesh Mahadu¹,Shobha Singarapalle²,Nandikolla Adinarayana¹,Chandu Ala³,Murugesan Sankaranarayanan³,Kumar Muthyala Murali Krishna²,Chandra Sekhar Kondapalli Venkata Gowri¹^ORCID

Affiliation:

1. Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, India

2. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh – 530 003, India

3. Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, 333031, India

Abstract

Twenty-eight compounds, viz., 1,8-naphthyridine-3-carbonitrile (ANC and ANA) derivatives, were designed and synthesized through a molecular hybridization approach. The designed compounds were evaluated for anti-TB activity against Mtb H37Rv strain.

Funder

Council of Scientific and Industrial Research, India

Science and Engineering Research Board

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA04262J

Reference46 articles.

1. Synthesis and Biological Evaluation of New 1,2,3‐Triazolyl‐Pyrazolyl‐Quinoline Derivatives as Potential Antimicrobial Agents

2. Drug-resistance inMycobacterium tuberculosis: where we stand

3. Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains

4. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies